EyePoint Pharmaceuticals Announces Expanded License Agreement with Betta Pharmaceuticals for EYP-1901 in China, Hong Kong, Macau and Taiwan

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Related Keywords

China ,Taiwan ,Watertown ,Massachusetts ,United States ,Hong Kong ,Macau ,Chinese ,Amy Phillips ,Jinhao Shen ,Christina Tartaglia ,Equinox Sciences ,Nasdaq ,Eyepoint Pharmaceuticals Nasdaq ,Betta Pharmaceuticals Co ,Green Room Communications ,Eyepoint Pharmaceuticals ,Betta Pharmaceuticals ,Eyepoint Pharmaceuticals Inc ,Point Pharmaceuticals ,Mainland China ,Nancy Lurker ,Chief Executive Officer ,Lieming Ding ,Diabetic Macular Edema ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Covid 19 ,Technology ,Health ,Business ,Globe Newswire ,